

Anna Bonjoch

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4953879/publications.pdf>

Version: 2024-02-01

37
papers

634
citations

623734

14
h-index

580821

25
g-index

37
all docs

37
docs citations

37
times ranked

1092
citing authors

#	ARTICLE	IF	CITATIONS
1	High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study. <i>Aids</i> , 2010, 24, 2827-2833.	2.2	140
2	Hypophosphatemic osteomalacia induced by tenofovir in HIV-infected patients. <i>Clinical Rheumatology</i> , 2016, 35, 1271-1279.	2.2	62
3	Long-Term Safety and Efficacy of Nevirapine-Based Approaches in HIV Type 1-Infected Patients. <i>AIDS Research and Human Retroviruses</i> , 2006, 22, 321-329.	1.1	48
4	Improvement in bone mineral density after switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: two-centre randomized pilot study (OsteoTDF study). <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 3368-3371.	3.0	43
5	High rate of reversibility of renal damage in a cohort of HIV-infected patients receiving tenofovir-containing antiretroviral therapy. <i>Antiviral Research</i> , 2012, 96, 65-69.	4.1	39
6	High Prevalence of Sarcopenia in HIV-Infected Individuals. <i>BioMed Research International</i> , 2018, 2018, 1-5.	1.9	36
7	Peak Bone Mass in Young HIV-Infected Patients Compared With Healthy Controls. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 65, 207-212.	2.1	30
8	Validation of estimated renal function measurements compared with the isotopic glomerular filtration rate in an HIV-infected cohort. <i>Antiviral Research</i> , 2010, 88, 347-354.	4.1	26
9	Switching the third drug of antiretroviral therapy to maraviroc in aviraemic subjects: a pilot, prospective, randomized clinical trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1382-1387.	3.0	25
10	Switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: changes in bone turnover markers and circulating sclerostin levels. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2104-2107.	3.0	25
11	Antiretroviral Treatment Simplification With 3 NRTIs or 2 NRTIs Plus Nevirapine in HIV-1-Infected Patients Treated With Successful First-Line HAART. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005, 39, 313-316.	2.1	18
12	High Prevalence of Signs of Renal Damage Despite Normal Renal Function in a Cohort of HIV-Infected Patients: Evaluation of Associated Factors. <i>AIDS Patient Care and STDs</i> , 2014, 28, 524-529.	2.5	16
13	Time of Progression to Osteopenia/Osteoporosis in Chronically HIV-Infected Patients: Screening DXA Scan. <i>PLoS ONE</i> , 2012, 7, e46031.	2.5	16
14	Removal of Dolutegravir by Hemodialysis in HIV-Infected Patients with End-Stage Renal Disease. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 2564-2566.	3.2	15
15	Prevalence, evolution, and related risk factors of kidney disease among Spanish HIV-infected individuals. <i>Medicine (United States)</i> , 2017, 96, e7421.	1.0	11
16	Randomised Study to Assess the Efficacy and Safety of Once-Daily Etravirine-Based Regimen as a Switching Strategy in HIV-Infected Patients Receiving a Protease Inhibitor-Containing Regimen. Etraswitch Study. <i>PLoS ONE</i> , 2014, 9, e84676.	2.5	11
17	Ten-Year Safety with Polyacrylamide Gel Used to Correct Facial Lipoatrophy in HIV-Infected Patients. <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 817-821.	1.1	10
18	Switching from a ritonavir-boosted PI to dolutegravir as an alternative strategy in virologically suppressed HIV-infected individuals. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 72, dkw504.	3.0	9

#	ARTICLE	IF	CITATIONS
19	Potential prescribing issues among older HIV-infected subjects in a Mediterranean cohort: Does the current prevalence give cause for concern?. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 1310-1317.	2.4	8
20	Association between polymorphisms in genes involved in lipid metabolism and immunological status in chronically HIV-infected patients. <i>Antiviral Research</i> , 2015, 114, 48-52.	4.1	7
21	Prospective Study to Assess Progression of Renal Markers after Interruption of Tenofovir due to Nephrotoxicity. <i>BioMed Research International</i> , 2016, 2016, 1-5.	1.9	7
22	High risk and probability of progression to osteoporosis at 10 years in HIV-infected individuals: the role of PIs. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2452-2459.	3.0	6
23	Prevalence of Ischemic Heart Disease and Management of Coronary Risk in Daily Clinical Practice: Results from a Mediterranean Cohort of HIV-Infected Patients. <i>BioMed Research International</i> , 2014, 1-8.	1.9	4
24	Impact of protease inhibitors on the evolution of urinary markers. <i>Medicine (United States)</i> , 2016, 95, e4507.	1.0	4
25	Management of bone mineral density in HIV-infected patients. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 845-852.	1.8	4
26	Similarly high prevalence of hypovitaminosis D in HIV-infected subjects with and without low bone mineral density. <i>Future Virology</i> , 2012, 7, 1127-1134.	1.8	3
27	A randomized pilot trial to evaluate the benefit of the concomitant use of atorvastatin and Raltegravir on immunological markers in protease-inhibitor-treated subjects living with HIV. <i>PLoS ONE</i> , 2020, 15, e0238575.	2.5	3
28	Long-term changes in bone mineral density after switching to a protease inhibitor monotherapy in HIV-infected subject. <i>New Microbiologica</i> , 2015, 38, 193-9.	0.1	3
29	Polymorphisms in LPL, CETP, and HL protect HIV-infected patients from atherogenic dyslipidemia in an allele-dose-dependent manner. <i>Journal of the International AIDS Society</i> , 2014, 17, 19557.	3.0	2
30	Association between lipid genetic and immunological status in chronically HIV-infected patients. <i>Journal of the International AIDS Society</i> , 2014, 17, 19555.	3.0	1
31	Accentuated aging associated with HIV in a Mediterranean setting occurs mainly in persons aged >70 years: a comparative cohort study (Over50 cohort). <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2021, , 1-8.	1.2	1
32	Ultrasound-Based Assessment of Preperitoneal Fat as a Surrogate Marker of Cardiovascular Risk: Comparative Study Between People Living with HIV and Controls. <i>AIDS Research and Human Retroviruses</i> , 2022, 38, 222-227.	1.1	1
33	Title is missing!. , 2020, 15, e0238575.		0
34	Title is missing!. , 2020, 15, e0238575.		0
35	Title is missing!. , 2020, 15, e0238575.		0
36	Title is missing!. , 2020, 15, e0238575.		0

#	ARTICLE	IF	CITATIONS
37	Prevalence, progression, and management of advanced chronic kidney disease in a cohort of people living with <sc>HIV</sc>. HIV Medicine, 2022, , .	2.2	0